GTM strategy

An adoption strategy covering audiences, positioning, channel readiness, rollout and measurable operating use.

Product decision
Position operational value accurately and enable the manual path.

Document type

GTM strategy

Status

Portfolio sample · written from my healthcare claims experience

Product decision

Position operational value accurately and enable the manual path.

Portfolio sample from my healthcare product experience. Requirements, thresholds and review records are illustrative; they are not employer documents or historical sign-offs.

In this document 7 sections

Market and adoption problem

This is an internal/platform adoption strategy: the product succeeds when operations and receiving teams can rely on it in their daily work. Purchasing or enabling an extraction component does not establish adoption. The first release serves an agreed medical-claims cohort; a platform migration has a separate audience, readiness assessment and cutover decision.

1. the product succeeds when operations and receiving teams can rely on it in their daily work
2. Purchasing or enabling an extraction component does not establish adoption
3. The first release serves an agreed medical-claims cohort a platform migration has a separate audience, readiness assessment and cutover decision

Segments and positioning

Position the value according to each audience’s task.

Segment	Problem / message	Proof needed
Claims operations	Less avoidable entry with accountable exceptions	Valid and failed-task walkthroughs
Customer care	Explain pending versus rejected versus final status	Consistent status definitions and escalation
Provider-data stewards	Turn mismatch volume into actionable quality feedback	Reason-level reports and original evidence
Receiving-system teams	Valid attributable handoff without duplicate work	Contract tests and acknowledgements
Leadership/control partners	Net value after rework and risk	Reconciled metrics and readiness evidence

Value proposition and limits

I position the product around reliable administrative completion, not guaranteed payment or clinical improvement. More than 400,000 paper claims were converted to EDI 837, an 80-person team was redeployed and the business saved about $1M a year. The separate provider interface improved latency and reporting; the platform work replaced a legacy claims integration. Those outcomes support different conversations and are not bundled into a single ROI claim. Medical 837 and retail pharmacy NCPDP workflows remain distinct.

1. reliable administrative completion not guaranteed payment or clinical improvement
2. More than 400,000 paper claims were converted to EDI 837 an 80-person team was redeployed and the business saved about $1M a year
3. The separate provider interface improved latency and reporting the platform work replaced a legacy claims integration
4. Those outcomes support different conversations not bundled into a single ROI claim

Medical 837 and retail pharmacy NCPDP workflows remain distinct.

Channels and enablement

Use operator demonstrations, role-specific job aids, customer-care status guidance and technical consumer contract reviews. Show a missing provider, ambiguous match, rejected 837 and delayed acknowledgement, not just the best-case extraction. Training requires the learner to explain why advancement is blocked and identify the authorized next step. Support material includes queue ownership, escalation, source evidence and safe retry behavior. Legal/compliance review data-use language; patient-safety partners contribute where processing changes could have consequential downstream effects.

1. operator demonstrations, role-specific job aids customer-care status guidance and technical consumer contract reviews
2. Show a missing provider, ambiguous match, rejected 837 and delayed acknowledgement not just the best-case extraction
3. Training requires the learner to explain why advancement is blocked identify the authorized next step
4. Support material includes queue ownership, escalation, source evidence and safe retry behavior

Legal/compliance review data-use language; patient-safety partners contribute where processing changes could have consequential downstream effects.

Rollout and readiness

Begin with approved sample and sanctioned test cases, then a bounded operational cohort only after release authority is established. The readiness package includes Q1–Q12 evidence, operator UAT, staffed exception handling, monitoring, rollback and the sample API load result. Publish p95 against the ≤500 ms at 50 requests/second target with cache/source paths and failures. Increasing exposure depends on quality and recovery capacity. Platform migration additionally requires consumer-specific comparison, isolated replay and reconciled in-flight inventory.

1. Begin with approved sample and sanctioned test cases
2. Publish p95 against the ≤500 ms at 50 requests/second target the sample API load result
3. a bounded operational cohort only after release authority is established
4. Increasing exposure depends on quality and recovery capacity

Platform migration additionally requires consumer-specific comparison, isolated replay and reconciled in-flight inventory

Adoption measures and stop conditions

Measure correct repeated use, eligible completion, exception age, rework, support contacts and downstream defects. Count unassigned and pending work; do not celebrate adoption because difficult claims disappeared from the denominator. An unintended duplicate, unsupported identity choice, missing record or access exposure stops expansion for investigation. If status confusion drives contacts, improve the shared language before acquiring more traffic. Product owns the adoption decision, operations owns readiness, engineering owns recovery and control partners own their release conditions. No reconstructed gate is represented as an executed historical sign-off.

1. Measure correct repeated use, eligible completion, exception age, rework support contacts and downstream defects
2. Count unassigned and pending work do not celebrate adoption because difficult claims disappeared from the denominator
3. An unintended duplicate, unsupported identity choice, missing record or access exposure stops expansion for investigation
4. Product owns the adoption decision operations owns readiness, engineering owns recovery and control partners own their release conditions

If status confusion drives contacts, improve the shared language before acquiring more traffic.

Feedback and expansion decision

During a bounded rollout, product reviews recurring operator workarounds, customer-care contacts and unresolved queue reasons alongside quantitative measures. A workaround that bypasses provider evidence is a control failure, not successful adoption. A confusing status may require language and training changes rather than new processing logic. The expansion review records which segment benefits, which remains unsupported and what additional capacity is required. Leadership receives options with a recommendation: continue the same cohort, narrow eligibility, correct a failure mode or expand after evidence. Broader exposure is earned through useful and reliable operation, not announced as a fixed destination.

1. product reviews recurring operator workarounds, customer-care contacts and unresolved queue reasons alongside quantitative measures
2. A workaround that bypasses provider evidence is a control failure not successful adoption
3. The expansion review records which segment benefits which remains unsupported and what additional capacity is required
4. continue the same cohort, narrow eligibility, correct a failure mode or expand after evidence Leadership receives options with a recommendation

Broader exposure is earned through useful and reliable operation, not announced as a fixed destination.